
Dec 16 (Reuters) - Nektar Therapeutics NKTR.O:
NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2% SALT SCORE REDUCTION
NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE
NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY RESULTS SUPPORTS ADVANCEMENT TO PHASE 3 DEVELOPMENT IN ALOPECIA AREATA
NEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONS